Using both prevention and reversal treatment modalities, we demonstrated the potential of the Gys1 ASO approach to serve as efficacious SRT in the Gaa−/− mouse model of Pompe disease. The gene discussed is GYS1; the disease is Glycogen storage disease due to acid maltase deficiency.